Testing effectiveness (Phase 2)Ended earlyNCT02859415
What this trial is testing
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Who this might be right for
Esophageal NeoplasmsLung NeoplasmsMesothelioma+2 more
National Cancer Institute (NCI) 3